Special issue: “MET as actionable target in cancer therapy”
- 1 January 2017
- journal article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (1), 1
- https://doi.org/10.21037/atm.2017.01.10
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsCancer Discovery, 2015
- Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC PatientsChemotherapy Research and Practice, 2012
- Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung CancerClinical Lung Cancer, 2012
- Targeting MET in cancer: rationale and progressNature Reviews Cancer, 2012
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancerBritish Journal of Cancer, 2008
- A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with RapamycinClinical Cancer Research, 2005
- Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.2003
- Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomasNature Genetics, 1997